Video

New hope for relapsed myeloma | Richa Thakur, MD

Posted by
HealthTree Logo HealthTree
• November 25, 2026

Description

In this presentation from the HealthTree Portland Myeloma Roundtable (November 7, 2026), Richa Thakur, MD explores four new drug classes reshaping multiple myeloma treatment and what these emerging therapies mean for patients across different stages of care.

Key topics covered in this session:

• Overview of four emerging drug classes in multiple myeloma care and how they target myeloma cells

• Where novel therapies fit into newly diagnosed and relapsed/refractory treatment sequencing

• Key efficacy, safety, and clinical trial considerations to discuss with your myeloma specialist

Timestamps:

0:00 Talk Overview and Goals

1:28 Relapsed and Refractory Myeloma

3:32 How to Read Trial Data

5:03 New Drug Classes Overview

6:14 How Bispecific Antibodies Work

8:54 Bispecific Combination Trial Results

11:20 Bispecific Side Effects: CRS and ICANS

15:21 Infection Prevention and IVIg

19:19 Belantamab Antibody Drug Conjugate

22:00 CELMoDs: Iberdomide and Mezigdomide

24:35 Choosing and Sequencing Therapies

30:30 Key Takeaways for Patients

Event details: https://healthtree.org/events/portlandrt2026

Transcript

So there's a few big topics I'd really like to cover. We have a lot of new drugs that have recently been approved over the last few years, different classes and what to do in that relapsed setting. We honestly don't really know what's best in certain cases. So a lot of the things that we do today are really tailored towards patients and looking at what side effects, what comorbidities they have, and really customizing the perfect plan for each patient. And I will talk a little bit about trial data, but I think for some people you guys are very well versed. And so some of this you probably will already know. But maybe for the people that are a little bit new to interpreting trial data, I at least wanted to have some simplified things of what to look out for, and a big bunch of like classes of the drug, some differences, the more recent trial results, and then how we choose what to give next for patients, and then of course, things that you can take with you to your doctor if you have questions later. And so to start, we've already had some really, really good presentations on the precancerous conditions, amyloid, smoldering, and also what to do with newly diagnosed myeloma. Right. So all of the drugs I'm talking about are for relapsed myeloma, which means it was already treated once and it came back or what we call refractory disease, which means when patients were given some form of treatment for a few months, it's worked a little bit, but not as much as we hope. And so these are the cases where we really want to pivot the chemotherapy to something different. And the other piece I just want to reassure all patients here and everybody, relapse is pretty common with multiple myeloma. Unfortunately it's a little expected. But we're getting better and better every day. And some of our newer lines of therapies are even doing better than what we initially gave patients. And so in old like cancer paradigms, they would teach you your first line of chemotherapy is the best one. The second line is probably not as good there. It is worse, right? And while that is often the case in some cases, in a lot of cancers with myeloma, it's difficult to predict. And some patients do a lot better on like future lines than they do on first ones. But that paradigm is still, I think, something that we do think about a lot when we're planning chemotherapy options. And so the reason these new treatments are really, really important nowadays for all of our patients is because traditionally and historically, patients that had gotten treatments from three different classes are what we call triple refractory disease had very poor outcomes. And this was honestly in the era where we didn't have as many good drugs to give patients. And so today, most patients, when they're newly diagnosed, they're already triple refractory by the time they have refractory disease or relapse, because they've probably already gotten Dara or a map, they've already gotten Revlimid, Velcade, or lenalidomide two in most cases. And so that's the reason why we need to think of newer drugs, new mechanisms of action to work on the second line setting, which is what we call when the myeloma first comes back. And so I will talk a little bit about clinical trial data. And so just, it can often get very cumbersome. And unfortunately, one of the paradigms with myeloma too, is that patients do live a very long time. And so most of our research trials, we can't really wait for true overall survival data, because we would be waiting years and years and years, even decades, to get that information from the study. And then by the time we get it approved to give to patients, we're already behind the eight ball like ten, 15 years. So nowadays we use other surrogate markers. So like MRD testing to approve the data earlier. And what that is, it's like a very specific measure of the myeloma from the bone marrow. And it gets an ultra- specific level of detection down to one in 10 to the minus sixth overall response rate is really just did the treatment work for most patients. And progression- free survival, or PFS, means how long can your myeloma be controlled with this regimen. And then of course with trial designs, there's two things I think are important to know their single arm versus a randomized trial. So single arm means everybody in the trial got the drug that they're looking at. Randomized means usually 50/50 ratios. But every trial split is a little different. So keep a screenshot in the back of your books or notes if you need this for later when we go over the data. And so, there's quite a few new classes out there. So bispecific antibodies, antibody drug conjugates, CELMoDs and then also CAR T therapy. Dr. Chen actually has a very excellent presentation for you later this afternoon on CAR T therapy. So I won't go into too much detail about CAR T, but we will talk about the other three. The only thing I want you to know about CAR T, though, is it's not ready the second you need it. It's something that your doctors will have to prepare. There's a little bit of a wait time, 4 to 6 weeks. These other three drugs And so in those cases, like if you're getting CAR T, you need some sort of what we call bridging or holding therapy, something to control the myeloma in the meantime. But these other three options of bispecifics antibody drug conjugates, CELMoDs, they're ready now the way like your dear is already writing in the pharmacy, right. You just give it to patients. That's what these are. And they have slightly different dosing recommendations, slightly different targets, but they all work really well. We just have to choose the right drug based on what else is going on with the myeloma when we pick. So the first mechanism I'm going to talk about is a bispecific antibody. And I will say this is one of the coolest things. When I first started working in oncology that just blew my mind. So everybody knows what a monoclonal antibody is like. Dara. Right. Like at least from historically, it's basically an antibody that has one arm and it just attacks whatever you pointed at. So if you're looking at Dara, it only attacks any mark like a protein that's like CD38 Bispecifics are really interesting because they have two different arms. So this is kind of like the ultimate matchmaker in myeloma. I really don't know how to describe it. So one arm will point to something that's in the immune system. So for myeloma drugs we usually do CD3. So it works on the T cells that are part of your own immune system. The other arm we pick a target that fights something very specific to myeloma. And so the bispecifics we have right now are target two proteins BCMA or GPRC5D. And the idea is this protein antibody comes in. It binds to the T cell on one side. It binds to the myeloma cell. And it brings the two together so your own body can help fight off the myeloma. And so what you can see in the data here it's actually really really effective. So these are overall response rates between different bispecifics, teclistamab and talquetamab that have shown really really great options. And when you look at old historic pre- bispecific data, most of the response rates were sort of in the 30%. I mean some were much better, some were much worse. But that's like a good landmark to think about. So these drugs already have been doing better than what we can expect. And from these I would say honestly teclistamab, elranatamab all work very similarly. They're all really efficacious. The way I honestly choose them is basically dosing regimen and then what your doctor already has on formulary. So I will say like at Hutch I'm very spoiled, I get my pick. But unfortunately sometimes in the community, based on what insurance covers or what's available at the site, I would start whatever at Hutch, for example, for a patient that they could continue at home long term. Talquetamab is a different target, so the first three are BCMA; Tal is GPRC5D, so that one you actually pick at a very different time point based on what else is going on with the myeloma. And so when you're looking at these results, right, the first graph I showed you was the bispecifics just by themselves, these are data points where we combine them with something. So this is something that we've learned in myeloma over the years. You know, if one drug does a good job two actually often does an even better job because they work in a mechanism called synergistically, kind of like two best friends that help each other to do more than they can do by themselves. And so when you look at MajesTEC-3 and MajesTEC-9, these are teclistamab- based regimens where the progression free survival or what we call basically the time a patient is cancer-free or the cancer is controlled was significantly longer for patients that got a bispecific earlier on in line than patients that didn't get bispecific single what we usually would do for standard of care. Now there is one piece that's a little tricky about interpreting this data for most patients. If you can see what patients were given these all all these patients the bispecific was paired with daratumumab. Right. And I think as you guys have already learned, most patients get daratumumab or maybe isatuximab when they're first diagnosed with myeloma. So the problem is I don't really know to this extent in terms of clinical trial data, how well a bispecific works with some other combination. So you can't always apply those numbers to your clinical scenario. But what you can actually take away for these cases is that they do work really, really well. We have more studies with other combinations, and they are moving earlier and earlier in the treatment trajectory. So like for example, Tel is really approved for much later lines. But we're thinking about bringing it sooner based on how well it's working. The MajesTEC-3 data for teclistamab with daratumumab is excellent. Unfortunately we just don't have a lot of patients that have never gotten Dara. That being said, though, we still give it for a lot of patients in this case. And what you can take away from this is some of these other bispecifics, are really doing an incredible job at controlling the myeloma. We just have to get very creative with what we pair it with to do to make sure it still works well. And the other piece with the bispecifics is these are actually really well tolerated. So there are a few main side effects you'll see across all of the bispecifics called CRS what stands for cytokine release syndrome. And then the other one is ICANS, which is basically a combination of immune mediated neurotoxicity. So most patients will have very mild forms of this. CRS is essentially kind of like an inflammation of your body, kind of it feels like as if you're sick. Patients might get fevers. Their blood pressure could drop, your heart rate could increase. And this is often treated with steroids. And same thing with ICANS. It's very unusual neurotoxicity. Sometimes you can see tremors, brain fog, forgetfulness. Otherwise it can be more severe neurological symptoms too. But the severe ones are usually pretty rare and very well tolerated. Like very rare. The ones that most patients have are really well tolerated. And the other piece, though, is that this data is actually from the trials before we usually manage them the way now. So we have more data that teaches us how to manage these toxicities better. And so the rates I see in the clinic of CRS is much less because instead of giving the treatment for CRS after for most patients we give a baby dose of some preventative treatment before. And so tocilizumab is the one of the drugs we will often give just preventative for a lot of patients on bispecifics. So they don't even have to worry about CRS later. The other piece that's also pretty common with bispecifics and much more with your BCMA bispecific. So this is teclistamab, this is elranatamab. This is linvoseltamab. Our infections. And so before in the older trials we didn't really know what to do to stop the infection. So there's a much higher rate of infections nowadays. We have much much better supportive and preventive strategies for this. And that's actually made a huge game changer with how well patients do on these drugs. And there's a few other combinations of like side effects too. Right. So like decreased blood counts, decreased, what we call immunoglobulins or hypogammaglobulinemia. But this is something that we've had more supportive measures to help fix. Tal is slightly different because it is a very different target. The GPRC5D. And the reason these two targets were chosen for bispecifics is because they're very, very specific to multiple myeloma. But the problem is with the GPRC5D target, it's actually present on some other type of epithelial tissues. So that means you see that same protein in your hair in your skin like in the GI tract. And so that's why patients that get Tal continued their myeloma can actually be really, really well controlled. But they may notice a very different profile of side effects like changes in their skin rashes, or like the growth of their nails isn't quite the same, or their taste completely changes, which is also why they often will lose a little bit of weight and sometimes even a lot more weight if they're not eating on Tal. But these side effects do get better, because what we do is start spacing out the drug. So for some patients, it may never go away entirely, but it's still pretty tolerable. But this is something that if your doctor does recommend talquetamab, I think it's a generally a very good option in terms of treatment, but it does require a lot of, working hand in hand with your doctor, the nutritionist, the rest of the team to make sure we maximize your quality of life while you're still taking this drug. And so, specifically with infections, you don't see this as much with talquetamab, although it is it is seen, it's much more common with the other three BCMA bispecifics teclistamab, linvoseltamab, and elranatamab. And the reason this is so common is the BCMA is very, very specific for your myeloma cells, but it does cause some collateral damage and can entirely wipe out your healthy plasma cells. And these are the same plasma cells that make the immune like the antibodies to build up your immune system. Right. And so before in the old trials, we weren't giving all of these because we just didn't know. But nowadays for most patients when honestly for all patients, when we start a bispecific antibody, they're started on IVIg at the same time. And then you're also recommended to take a few different like antibiotics and antiviral medications as a preventative measure. So I would say most patients here probably are already on acyclovir if you have myeloma. Because honestly, all of the myeloma drugs increase your risk of shingles. So that's something we would continue with the bispecific. But we would also add another drug called Bactrim to prevent a different kind of what we call pneumocystis or like PJP pneumonia. And then the vaccines of course are very very important. Right. Like get your flu, get your COVID shot not just with bispecifics but with all patients. With myeloma, there's some data on like different efficacy on timing based on what when you get whatever chemotherapy regimen you're on. But in general, most patients should get these vaccines. It's probably a really good idea to bring them up with your doctor, so you can optimize the timing. But to be honest, even if you don't get like the full 100% of the vaccines, I strongly believe the vaccines will still give you a lot, at least some immunity. Right? Like 70% is better than zero, even if you can't get the full 100% from the vaccine. And the other piece of all of the paradigms for dosing bispecifics as we start up front with a much more intensive regimen. So patients are given these doses at like the way I would think about it as like 1% of the dose, then we go up to like five, 10% of the dose and then to the full dose with whatever bispecific you start. And then most of the bispecifics you get once a week for a certain amount of time, we start spacing it out to every two weeks, and then every four weeks after that, the dosing regimens a little different with each one. So I'm trying to be just a little general. So it makes sense for the whole group. But it's really nice when patients are spaced out because the side effects actually get better the more you space out the drugs over time. And of course, like with fevers, it's really important to make sure you call your doctor because, a lot of patients in this case, you could have CRS as a complication from your bispecific. Right. So don't just call your primary care doctor for the future. It's really important that you call your oncologist because you don't want to miss a side effect of the treatment and only treat as if it's an infection. So okay, so, but bispecifics have while we get this up, I'll just keep talking about the bispecifics. They've really changed the treatment landscape quite a bit, and we're still working on the optimal pairing for so many of these drugs. But, to be honest, they're really great options in between. And because as target overlaps with other things like CAR T or your antibody drug conjugates, it really does require having very close collaboration with your oncologist. So we can plan not only what you get for this line, but what I would give you for the line after and the one after that too. So moving on to belantamab. This is similar target. It also works on BCmA, but this is an antibody drug conjugate. And so really what this is, it's also a kind of like a monoclonal antibody. But it has these arms that hook onto very cytotoxic chemo. And essentially you can think of this as kind of like a grenade. So it's basically this this monoclonal antibody will find the target the BCmA on the myeloma cell. It sneaks in and then it releases all what we call the cytotoxic payload, essentially all the grenades of chemotherapy inside the myeloma cell. And that essentially will destroy the myeloma cell, which is great because it works really, really well. One thing you'll notice that's different about belantamab compared to like what you need with bispecifics or CAR T is that there is no T cell involved here. So a lot of times if you have immune like T cell exhaustion from other therapies, belantamab can still work in this case. And so it also works pretty well. It's approved in combination with vel or or Pomalyst in the EU but not in the US yet. Works really, really well. Good options, but it's something that you do need to be careful with how you give. Because if you give a BCMA-targeted therapy, it makes it hard. Like your next line, if it's best, doesn't work as well. So you do need to have a plan to do something, what we call like sandwiching or like sequencing therapy. So there's more space in between. And the results for the phase three data are incredible. One thing I will say is one of the biggest toxicities are related to the eye. So it's very important that you see your ophthalmologist every single time your oncologist tells you to see your ophthalmologist on schedule. This drug was pulled off of the market a few years ago because of the eye toxicity. They have changed the dosing patterns, put it back on the market because it's safer to give now. And essentially the way you give it is you give the drug and you see the ophthalmologist, whenever there's changes in your vision, you cut back the dose, hold the belantamab until the vision gets better, and then you wait for the recovery before you restart it. And that's kind of like a very superficial way to dose it. But they they've made a lot more changes to make that dosing safer for patients. It's still, I will say, the corneal toxicity still my least favorite toxicity of all of the drugs. But it is a very good option for some patients. And then now moving on to CELMoDs, which are the newest hot new item on the market. And so you can think of this as Pomalyst and Revlimid, like big brother that's older, faster, stronger, and essentially what it is, it's another pill that works very similar binds to a protein called cereblon, and that releases two other proteins called Ikaros and Aiolos. These really will help the myeloma cell grow without the CELMoD in place. When those are released, it triggers this downstream cascade of essentially destroying all of the extra, the extra proteins and essentially helping decrease the myeloma cells and inducing what we call apoptosis, which is cell death. So and what's great about this is even if you have resistance, so like your myeloma doesn't like the Revlimid doesn't work. Lenalidomide doesn't work. You can still use a CELMoD. So we have one CELMoD that's already approved. That's iberdomide in combination with daratumumab. Same issues as with like the bispecifics and Dara. Right. Most patients that would be eligible for second line have already gotten Dara, but still a good option to keep on the back end. There's a second drug called mezigdomide, which is up on the market. And it's supposed to be really great. It's been tested in combination with car and member and also works really, really well. The biggest toxicity with this is neutropenia. So patients that get this will probably need some sort of growth like growth hormone shot specifically G-CSF. It's worse within the first 2 to 4 months of when you start treatment. And in my like all of the patients I've started on this have probably needed G-CSF every week for the first few weeks that you started. So in general, it works really, really well. It's being approved in second line like data. There's more trials about using it post-transplant for maintenance settings. But this we still don't know yet. And then the other piece though is if you do this before we don't really know how the collection will sometimes work too. So very good option for a lot of these, but I feel like the issue with all of the trials is it's you want to choose the drug that works best today. That's also going to keep doors open for the next line tomorrow. And that's why it's very hard for me to say, give this one second line, because it's very unique to each patient. And these are good options to give to any patient. You just have to pick based on what they've had in the past to move forward. And so that kind of gets at how do we choose our therapies. Right. So a directed therapy like it doesn't matter if it's an antibody drug conjugate, if it's a CAR T, if it's a bispecific, you can give them back to back. They will work a little bit, but you don't get the full power when you give them back to back, compared to if you put something else in between. So, for example, if I had a patient that had like a car BCMA CAR T, I see them after CAR T for their first relapse post-CAR T I probably wouldn't give them a BCMA bispecific you could consider like a cell mod you could consider like Kyprolis or Pomalyst if they hadn't had it before. And then for the relapse after, go back and give the BCMA because that helps the targets regenerate. The other piece to is it depends on how quickly the relapse happens when when there's a slower relapse, you have more time for things that take longer, like CAR T. When there's a very quick relapse, you really sometimes will have to pick your bigger guns that will work faster. Like tell them about your bispecifics. Different treatments are limited to your kidneys or your liver. And so that's another piece that we do have to adjust with dosing. And then of course, like the other toxicities right that each drug has some toxicity. We have to choose what's going to be the best option with that combination. And then I will say like logistics makes a big difference about this. Not every center can give bispecifics. Not every center can give CAR T. Not every center has like antibody drug conjugates on formulary. And so, I think every patient should be referred to a center that can evaluate for you for all of these therapies. So that way you can choose what you would want for yourself. But sometimes driving three hours every week is not a feasible option, right? If that's the closest center that gives bispecifics. So we have to come up with something else for you. But as a patient, I would I would at least want to know this is an option, but I just don't want to choose someone that's going to make me drive three hours. I'd rather pick the one where I can just go down the street for an hour or two. Okay. And so, essentially in terms of like the biggest principles that we try to do, right, we want to rotate all of the mechanisms, mix and match things, space out your BCMA directed therapy. And then also there are certain things that will use up your T cells bispecifics, CAR T, certain chemo like bendamustine. So we try to avoid those based on avoid them as the treatment right before something that's going to require like a T cell directed therapy. And then switching the targets is very, very important because you can't really use BCMA. You can use it like it's not necessarily wrong. You just won't get as good mileage if you do BCMA after BCMA, if you do like BCMA with them, something that's not BCMA and then come back to BCMA after. And so when you look at all of the treatment options for patients, right, it's kind of hard to know what to give. So for example, like if you had a relapse you were already treated with like art, like RBD problem. But your myeloma was diagnosed before daratumumab was approved for frontline. And you have a lot of options. You could probably go to CAR T. You could probably try the antibody drug conjugate, which is belantamab. You could try teclistamab. You could even try Dara IBR you could even do like like Kyprolis with Pomalyst, or Dara with one of those drugs. Right. So you have a lot of options in this case, but not all of them are going to be the best option for you based on what else is going on with your other medical condition. So we really want to pick one so that we can want to start. That really matches the best side effect profile. For example, if you live maybe like in terms of CAR T centers, like in Portland, we're really lucky we have OHSU right. In Seattle, I'm really like spoiled. I have Fred Hutch that can also do down the line, but not every patient lives this far. So lives that close to be able to relocate to one of these centers. So maybe like those are patients where it would be a really good option to do a CELMoD or like belantamab in between and then say you already had some sort of directed therapy like you were given teclistamab or you had to. I would say CAR T is not a good option right after that. But it would be a good option maybe for like a third or like a relapse after talquetamab. It's an interesting drug you could use too. But that also has issues with T cell exhaustion moving forward. So so for some of these cases you really have to be very careful what you give next because, this is a very difficult situation to pick one chemo and which might limit options or limit the efficacy of what comes next. And I know it's hard because I think sometimes people just want to know what what should I get for a second line. And this is an area that we still need a lot of research, a lot of data. And so the way myeloma specialists are working on this, as we look at what you had before, we look at what medical problems you have, and we customize a plan for you. And so what I'd probably recommend for every patient is we have very good oncologists all over the country. Sometimes it's also really helpful to ask your oncologist to speak with specifically a myeloma specialist because they have, like a myeloma specialist, will have access to treatments that your local oncologist may not have, but we can partner with your local oncologists to bring you those therapies to. In that way, you would never lose your local oncologists. We want to work with them too. So that way it's really like two people looking out for you, not just one. And so lastly, I know I threw a lot at you, but these are the few things I want you to take away. So bispecifics work really, really well. They have two different targets based on what treatments we give you. You can get them as injections. One is IV, though, and you start off with more intense therapy. Space it out. And the biggest toxicities would be infections. And that inflammation that we talked about, CRS, and the neurotoxicity, the ICANS and all patients should be on IVIg with the BCMA bispecifics, acyclovir, and PJP prophylaxis with Bactrim for these cases. And please don't forget the vaccines. So this was for bispecifics. CELMoDs, similar, right. Like these were kind of like Revlimid or Pomalyst 3.0. They work really really well. Only ones available. It's an oral pill you can take at home. It's given on a 21 day cycle or like 21. Sorry, 21 day or sorry 21 days of taking the pill. But like you get a week off. So the cycle is 28 days. And so similar to how you would take Revlimid or Pomalyst and also really really works well. But it will cause a lot of neutropenia at the beginning. And so you would need like close follow up and monitoring with your local oncologists for G-CSF injections. And then so for caregivers make sure you know to keep records, bring your schedules with you. Plan for phases where there's more time that you might have to spend inpatient versus outpatient. And please don't forget to take care of yourselves to. I think everyone gets focused on patients with myeloma, but there's a lot for caregivers that you guys do take on as a burden. And so if you guys want to take a screenshot of this, these are questions you could probably bring up for your next oncologist meeting. And basically I would say is like, did the trial show patients that were relevant to me? Am I eligible for clinical trials, and what are you planning after? This is really like the three big ones. I would always make sure to ask. And then, essentially more key takeaways, which we've already gone over if you guys want that slide. And thank you guys. Really appreciate it.